Nanotechnology Now - Press Release: "Epeius announces phase I/II trials of Rexin-G in chemo-resistant metastatic pancreatic cancer"

Home > Press > Epeius announces phase I/II trials of Rexin-G in chemo-resistant metastatic pancreatic cancer

Abstract:
Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology.

Epeius announces phase I/II trials of Rexin-G in chemo-resistant metastatic pancreatic cancer

San Marino, California | Posted on September 10th, 2010

Following up on its advanced US phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer molecule, which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G seen in the process of tumor eradication - revealing the "smoking gun" of precision, tumor-targeted killer gene delivery amidst a veritable "sea" of actively dying (apoptosing) tumor cells. Equally as important was the clinical finding that surgical oncologists were able to do more for cancer patients after the metastatic disease was brought under control by Rexin-G treatment.

Based on the adaptive Phase I/II study design, which included an FDA allowance for surgical intervention to be added to the treatment protocol in cases where repeated Rexin-G infusions had served to control the cancer and halt disease progression, the report describes the use of Rexin-G as both neoadjuvant therapy (before surgery) and as adjuvant therapy (after surgery) to prevent post-surgical spread and disease recurrence. Remarkably, the excised tumor(s) showed the process of Rexin-G accumulation within the tumors, as well as the molecular mechanisms of tumor cell destruction, with an unprecedented level of histological high-definition.

The landmark paper, published in the latest issue of Oncology Reports demonstrates the physical accumulation of the intravenous Rexin-G nano-medicine within the metastatic tumor prior to its surgical excision. It additionally reveals the selective accumulation of the Rexin-G nanoparticles on the surfaces of the target cells, i.e., pancreatic cancer cells and their proliferative vasculature, which is a distinctive property of the tumor-targeted nanotechnology platform. Using elegant immunohistochemistry to identify the process of active cell death (apoptosis) enforced by Rexin-G, the molecular mechanisms of precision tumor-targeting and selective cell death have never been more vividly displayed. It bears mentioning that the pancreatic cancer patient highlighted in this histological study is currently in surgical remission, with no new lesions during Rexin-G treatment and no disease recurrence going on six months after the Rexin-G / Surgical Excision / Rexin-G treatment combination.

####

For more information, please click here

Contacts:
475 Huntington Drive,
San Marino, California 91108
Tel: 626-441-6695
Fax: 626-441-6692

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: